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Abstract
Induction of fetal hemoglobin (Hb F) is an important therapeutic tool in ameliorating 
complications of sickle cell disease. Nitric oxide has been implicated in the mechanism of Hb F 
synthesis induced by hydroxyurea (HU). This study examined whether zileuton (ZL), a structural 
analogue of hydroxyurea, possessed Hb F inducing properties and the potential role nitric oxide 
plays. ZL caused a dose-dependent increase in ￿-globin expression in K562 cells. This effect was 
confirmed by a dose-dependent increase in Hb F synthesis in erythroid progenitors from
individuals with sickle cell anemia and normal hemoglobin genotypes. L-arginine had no effect 
on Hb F production; however, it dose-dependently inhibited ZL’s ability to induce Hb F. The 
nitric oxide synthase inhibitor, N
G-monomethyl-L-arginine (L-NMMA), inhibited L-arginine’s 
effect and restored ZL-mediated increase in Hb F synthesis. In addition, 8-(4-
chlorophenylthio)guanosine 3’,5’-cyclic monophosphate (8-PCPT-cGMP), inhibited ZL-
mediated induction of Hb F synthesis. When comparing L-NMMA effects alone on ZL and HU, 
a partial reversal of increased Hb F synthesis was seen only with HU. Neither L-arginine alone 
or in combination with L -N MMA effected hydroxyurea-mediated induction of Hb F 
synthesis.This study demonstrates that ZL induces Hb F through a mechanism that involves L-
arginine/nitric oxide/cGMP in a manner distinctly different from  HU .
e-mail:   jhaynes@usouthal.edu
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Introduction
Zileuton (ZL) [(N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea], is a specific inhibitor of 
5-lipoxygenase (5-LO) which results in decreased formation of leukotrienes (LTB4, LTC4, LTD4, 
and LTE4)
1. Structurally, ZL contains N-hydroxyurea (HU) .
2 This study investigated whether or 
not ZL can stimulate fetal hemoglobin (Hb F) synthesis in erythroid progenitors as has been 
observed with HU. Currently HU is the only Federal Drug Administration approved agent 
used to stimulate Hb F synthesis with proven efficacy in the treatment of sickle cell disease. HU
has been documented to reduce the severity and frequency of painful vaso-occlusive crisis, the
incidence of acute chest syndrome, 
3,4 and mortality 
5 in sickle cell anemia (HbSS). Despite its 
use in HbSS, the mechanism of action by which HU induces Hb F remains uncertain. HU is 
cytotoxic and inhibits growth of burst forming unit-erythroid (BFU-E) colonies in a dose-
dependent manner while Hb F levels increase. The decrease in BFU - E colony growth observed
with HU treatment is related to interruption of DNA synthesis in rapidly dividing late erythroid 
progenitors by   inhibition of the enzyme , ribonucleotide reductase. This leads to a transient arrest 
of hematopoesis. Suppression of BFU-E colony growth has been demonstrated to enhance 
premature commitment of earlier progenitor cells, accelerate erythropoesis, and increase survival 
of sickle red blood cells containing Hb F.
6-8 
Nitric oxide has been implicated in the regulation of Hb F induction by HU, which was 
recently shown to react with heme proteins to generate nitric oxide.
9-11 Ikuta, et al., demonstrated 
that an intracellular pathway which includes soluble guanylate cyclase and cGMP-dependent 
protein kinase plays a role in the induction of ￿-globin gene expression in two independent K562
erythroleukemic cell lines.
12 Most recently, Cockic, et al. demonstrated that HU induces Hb F by 
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the nitric oxide-dependent activation of soluble guanylate cyclase in K562 cells and human 
erythroid progenitors.
13
While structurally ZL contains HU, there is no published data that documents whether ZL 
stimulates Hb F synthesis in primary erythroid progenitors.
6-8
 In the present study, we
demonstrate ZL is a potent inducer of ￿-globin mRNA in normal and sickle erythroid progenitors 
and in K562 cells. This study further demonstrates that ZL decreases BFU-E colonies in cell 
culture and stimulates Hb F synthesis similarly to that observed with HU. We postulated that ZL 
induced Hb F through a nitric oxide dependent pathway as previously suggested with HU. We 
found that ZL induction of Hb F synthesis occurs through a mechanism that does not involve the
nitric oxide/cGMP pathway as demonstrated for HU. Further more we observed that the nitric 
oxide/cGMP pathway does play a negative regulatory role in ZL induction of Hb F in contrast to
HU. 
Materials and Methods 
Materials.  Bovine serum albumin (BSA, 66,000 mol wt), and L-arginine were purchased 
from Sigma Chemical (St. Louis, MO).  Zileuton (ZL) and hydroxyurea (HU) were purchased 
from the University of South Alabama Pharmacy (Mobile, AL). N
G-monomethyl-L-arginine (L-
NMMA) was purchased from RBI (Natick, MA). PMA and A23187 were dissolved in dimethyl-
sulfoxide (DMSO).  ZL was dissolved in 95% ethanol. HU, L-arginine, and L-NMMA were
dissolved  in  sterile  water. 8-(4-chlorophenylthio)guanosine  3’,5’-cyclic  monophosphate  (8-
PCPT-cGMP) was purchased from BIOLOG (Bremen, Germany) and dissolved in phosphate 
buffered saline.
Blood collection.  All participants gave informed consent and the Institutional Review 
Board approved the protocol.  During steady-state, blood samples (40ml) were obtained from 
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individuals with homozygous sickle cell anemia in the sickle cell clinics at the University of 
South Alabama. Whole blood samples were collected in syringes containing heparin and utilized 
within 48 hours of collection.  Individuals transfused within 6 weeks of sample procurement 
were  excluded  from  this  study.    Sickle  cell  anemia  was  documented  by  hemoglobin 
electrophoresis on each subject.
Cell Culture. Human K562 erythroleukemic cells were grown in suspension cultures in 
RPMI-1640 containing 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (0.1 
mg/ml)  in  a  humidified  incubator  at  37ºC,  5%CO2/95%  air  atmosphere.    The  following 
experimental conditions were analyzed in triplicate with 0.3 X 10
6 cells per well: an untreated 
control, ZL dissolved in 0.1% DMSO at final concentrations of 20, 40, 50, 75 or 100µM, HU at 
50, 75 or 100µM and two positive controls hemin (50µM, Sigma) and sodium butyrate (NB, 
Sigma, 2mM).  The K562 cells were induced for 48 hours then RNA isolated for further analysis.  
Cell viability was determined by 2% trypan blue exclusion at times 0 and 48 hours. 
RNase Protection Analysis. RNA was isolated using RNA Stat-60 (TEL-TEST "B", Inc., 
Friendswood,  TX)  according  to  the  manufacturer's  instructions.  In  brief,  cell  pellets  were 
suspended in RNA Stat-60 (1 ml) and the RNA was precipitated with isopropanol.  mRNA levels 
were  quantitated  by  RNase  protection  assay  (RPA)  with  probes  designed  to  yield  protected 
fragments  for  human  ￿-globin  (Hu￿)  and  the  internal  control  glyceraldehyde-3-phosphate 
dehydrogenase (GAPD) as previously described.
16 Hu￿ mRNA levels were normalized to that of 
GAPD and compared to untreated K562 cells.
BFU-E Colony Growth.  Mononuclear cells were isolated from the peripheral blood of 
each  participant  studied  by  density  gradient  centrifugation  using  Histopaque-1077  (Sigma). 
Erythroid  progenitors  were  incubated  in  methylcellulose  culture  medium  as  previously 
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described.
16
ZL was added on day 0 at 25, 50, 75 or 100µM concentrations for 14 days at which 
time the number of BFU-E colonies were counted on an inverted microscope and harvested for 
hemoglobin determinations. We previously published similar experiments for HU to analyze Hb 
F inducibility in  erythroid progenitors.
6 Informed consent was obtained from all participants 
following the University of South Alabama Institutional Review Board guidelines.  
Hemoglobin  F  determination.  After  14  days  of  incubation,  erythroid  progenitors  were 
collected, washed in PBS and then lysed at room temperature in 200µl of water.  The supernatant 
was split into two tubes, one for total hemoglobin determination and one for Hb F determination. 
Fetal hemoglobin was measured as a percent of total hemoglobin, normalized to total protein by 
alkaline denaturation as published previously.
6,16
Statistics.  All results are presented as means ± SEM.  Statistical analyses were performed 
using the unpaired Student's t test and one-way analysis of variance (ANOVA).  Tukey's test and 
Dunnett's
17 was used for multiple comparisons when ANOVA indicated statistically significant 
differences between or within groups.  Differences  were  considered  to  be  significant  when p< 
0.05.
Results 
Zileuton  augments ￿  gene  mRNA  levels  in  K562  cells.      Several  pharmacological  Hb  F 
inducers such as HU, 5-azacytidine,
18 erythropoietin,
19didox,
20 and butyrate
21 alter ￿-globin gene 
expression in culture.  Although the correlation between in vitro response and in vivo Hb F 
production is not necessarily direct, the induction of ￿-globin gene activity in culture is a good 
indicator of potential clinical usefulness.  Therefore, we analyzed the ability of ZL to induce ￿-
globin gene activity at the mRNA level. K562 cells were cultured in ZL from 0 to 100µM or HU 
(50µM to 100µM) for 48 hours.  Total cellular RNA was analyzed by RPA for ￿-globin mRNA 
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levels.  We observed an increase in ￿-globin mRNA for ZL at 20µM with a maximal increase at 
75µM (Figure 1A). The level of ￿-globin gene mRNA synthesis was quantitated relative to the 
internal control, GAPD.  As shown in  Fig. 1B, we observed  a 4.1-fold increase in ￿-globin 
mRNA  at  a  75µM  ZL  concentration  as  compared  to  a  2.7-fold  increase  for  HU  at  100µM 
(p<0.05).  Of note is the observation that ZL increased ￿-globin mRNA 2.6-fold at the 20µM 
concentration demonstrating comparable induction to 100µM HU (Fig. 1B) .
K562 cell viability was decreased 10% when measured by trypan blue exclusion at 75µM and 
100µM concentrations for both ZL and HU.  The level of ￿-globin gene induction was 3.9-fold 
and 10-fold for 2µM sodium butyrate and 50µM hemin, respectively.
Zileuton induces fetal hemoglobin in primary erythroid progenitors.  The parent 
compound HU is known to induce Hb F production in vivo in sickle cell patients treated for an 
Fig. 1.  ￿-Globin gene induction by zileuton in K562 cells.  K562 cells 
were treated with zileuton (ZL) at 20 to 100µM  concentration or 
hydroxyurea (HU) 50 to 100µM  concentrations for comparison.  ￿ globin 
mRNA levels were quantitated by RNase protection assay (RPA) with a 
human ￿ (Hu￿) and internal control gylcearaldehyde-3-phosphate 
dehydrogenase (GAPD) probes to yield protected fragments of 170-bp 
and 316-bp respectively.  Panel A contains a representative RPA gel 
showing the mRNA bands for ZL treated cells on the left and HU treated 
cells on the right.  Panel B shows the quantitative values for Hu￿ and 
GAPD mRNA production by phosphorimager analysis.  The untreated 
K562 samples (0 µM) were normalized to one (black bars).  The total 
increase in ￿ mRNA was calculated as a ratio to GAPD to control for 
variations in sample loading for ZL (white bars) or HU (gray bars) treated 
K562 cells.  Sodium butyrate (NB, gray striped bars) and hemin (HE, 
white striped bars) were used as positive control for ￿ gene induction.  
*2= NB at a 2 mM concentration.   
Fig 1
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extended period and in primary erythroid cell culture. Therefore, we analyzed the capability of 
ZL to induce Hb F in HbSS erythroid progenitors, grown from peripheral blood mononuclear 
cells (MNC). Each experiment was performed in triplicate. BFU-E colonies were grown in 
methylcellulose media supplemented with erythropoietin, interleukin-3, granulocyte-
macrophage-colony-stimulating factor, stem cell factor and ZL at concentrations from 0 to 
100µM. The mean BFU-E colony number was 116.0 + 15.2 without ZL compared to 13.3 + 2.9
at 100µM concentrations, p< 0.01 (Table 1). 
     Table I.  Effects of zileuton on BFU-E colony growth and fetal hemoglobin production in primary erythroid cultures.
Zileuton Concentrations (µM)
Despite the decline in BFU-E colonies, Hb F levels increased from 3.5 + 1.2 to 16.0 + 1.8
(p<0.01), thus demonstrating the ability of ZL to induce Hb F production in primary erythroid 
progenitors. Pair-wise comparisons for BFU-E at 0µM and 50, 75, and 100µM were significant 
at p<0.01.  Pair-wise comparisons for Hb F at 0µM and 75-100µM were significant at p< 0.01.
The correlation coefficient between the number of BFU-E colonies or percent Hb F versus the 
0 25 50 75 100
Patient 
No.
BFU-E 
 
Hb F BFU-E 
 
Hb F BFU-E 
 
Hb F BFU-E 
 
Hb F BFU-E 
 
Hb F
1     87    2     61      4     47     7       27          11     12     14
2   135    7     91     11     72    14       43    18       7    21
3
4                
  148
    93
   2
   3
  137
    86
     3
     5
    62
    66 
     6
     7
      23
      34
   11
     9
    13
    21
   13
   16
Mean     93    3 93.8   5.8  61.8    8.5    31.8  12.3   13..3 16.0
± SEM  15.2 1.2 15.8   1.8   5.3    1.8      4.4    2.0    2..9   1.8
￿ value __ __ > 0.05 >0.05 < 0.01 > 0.05 < 0.01 < 0.01 < 0.01        <0.01
 BFU-E= burst forming unit-erythroid, Hb F= fetal hemoglobin in percent (%)
￿ value represent a comparison of BFU-E colonies and Hb F in the absence of zileuton (0µM) versus 25 to 100µM 
   concentrations.
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different ZL concentrations was -0.90 and +0.79, respectively (p<0.05). These results are 
comparable to data we previously published for HU.
6 A dose-dependent 8.7-fold decrease in 
BFU-E colony number (p< 0.05) was observed at 100µM ZL as compared with control. Similar 
studies performed with HU (0 and 100µM) resulted in a  21.3- fold decrease for HU in BFU-E 
colonies grown from sickle cell anemia patients (p<0.05). Despite less change in the number of 
BFU-E growth with ZL, we observed a 4.6-fold increase in Hb F compared to a 3.8-fold increase
(5.1 + 1.0 to 19.4 + 1.5) for HU suggesting comparable Hb F induction for both drugs.  
Next the effect of ZL on ￿-globin gene expression was assessed in erythroid progenitors 
obtained  from  normal  donors.    Utilizing  the  same 
protocol  described  above,  BFU-E  colonies  from 
normal donors were measured in the presence of ZL 
at 0 to 100µM concentrations. In normal erythroid 
progenitors,  we  observed  a  decrease  in  BFU-E 
colony  number from 94.0  + 30.6  to  10.1  + 2.4  (Fig. 2A) and an increase in Hb F from 1.4 +
0.05%  to  6.0  +  0.38%  (Fig.  2B).  This  pattern  was  similar  to  that  obtained  for  sickle  cell 
progenitors. Of note is the lower average BFU-E colony number for normal progenitors.  This 
Fig. 2.   BFU-E colony growth and fetal hemoglobin production in the 
presence of zileuton for sickle cell and normal individuals in 
methylcellulose culture.  Peripheral blood mononuclear cells were 
cultured as described in Material and Methods.  The results are expressed 
as the number of BFU-E colonies per 3 X 10
5
mononuclear cells (MNC).  
White bars represent sickle cell and gray bars normal samples.  Panel A 
demonstrates the BFU-E colonies on day 14 in the presence of zileuton at 
0 to 100 µM concentrations.  Panel B represents Hb F for sickle cell 
(white bars) and normal samples (gray bars).  Note Hb F induction for 
both groups tested.
Fig. 2
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Fig 3
represents a 9.3-fold decrease and 4.3-fold increase in BFU-E and Hb F, respectively. Pair-wise 
comparisons  of  BFU-E  colony  growth  for  normal  samples  revealed  significant  decreases 
between ZL, 0µM, and the 50, 75, and 100µM concentrations (p<0.05). Similarly, Hb F levels 
were significantly increased at ZL concentrations of 50, 75 and 100µM (p<0.05).
L-Arginine  dose-dependently  reverses  the  effect  of  zileuton  in  sickle  primary  erythroid 
progenitors. Based on data previously published with HU, the nitric oxide-dependent activation 
of  soluble  guanylate  cyclase-protein  kinase  G  pathway  in  primary  erythroblast  constitutes  a 
mechanism that regulates expression of the ￿-globin gene.
12 In this study, the effect(s) of the 
nitric  oxide  donor,  L-arginine,
22,23  on  ZL  induction  of  Hb  F  in  primary  sickle  erythroid 
progenitors  in  culture  was  assessed. L-arginine  (0-100  µM)  dose-dependently  reversed  ZL
(50µM) suppression of BFU-E colony 
growth  and  stimulation  of  Hb  F 
synthesis (Fig. 3). In contrast, L-arginine (100µM) did 
not reverse the suppression of BFU-E colony growth
and  stimulation  of  Hb  F  synthesis  seen  with  HU, 
100µM  controls (Fig  4A  and  4B). When  sickle 
erythroid  progenitors  were  treated  with  L-arginine 
(100µM) alone, there was a 31% increase in BFU-E 
Fig 3.  Effects of increasing concentrations of L-arginine 
on  zileuton  treated  erythroid  progenitors  isolated  from 
patients with homozygous sickle cell anemia.  Cells were 
cultured  on  methylcellulose  culture  media  and  treated  with 
zileuton (100µM) as described in methods.  L-arginine (10-
100µM) was added at the beginning of the incubation period.  
The  number  of  BFU-E  colonies  (￿-￿)  and  levels  of 
hemoglobin F (Hb F, ￿-￿) were measured after 14 days of 
incubation.    Data  are  expressed  as  mean  ±  SEM  of  4
experiments done in triplicate.  *p<0.001 c/w baseline (BL); 
BL denotes the number of BFU-E colonies or percent Hb F 
measured in cultured cells not treated with zileuton. The 0µM 
point denotes the number of BFU-E colonies or percent Hb F 
measured in cultured cells treated with zileuton alone.  ￿ p< 
0.01 c/w L-arginine, 0µM ; ￿ p< 0.05 c/w L-arginine, 0µM. ￿
p<0.001 c/w L-arginine, 0µM. 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 11
Fig  4. Effects  of  L-arginine  and  L-NMMA  on 
hydroxyurea-treated  erythroid progenitors isolated from 
patients  with  homozygous  sickle  cell  anemia.    The 
experimental conditions were the same as in Fig 3.  L-arginine 
(ARG, 100µM) effects on hydroxyurea (HU)-treated (100µM)
erythroid progenitors in the absence and presence of the nitric 
oxide  synthase  inhibitor,  N
G-monomethyl-L-arginine  (L-
NMMA,100µM)  were  assessed.  The  number  of  BFU-E 
colonies (A) and percent Hb F (B) were measured as described 
in the Methods.  Data are expressed as mean ± SEM. n = 4 in 
each  group.  Each  experiment  was  done  in  triplicate.  *  p  < 
0.001 compared with control (CON).
colony growth as compared to control (p< 0.01). L-arginine had no effect on Hb F synthesis in 
the absence of ZL treatment of sickle erythroid progenitors in culture.
8-PCPT-cGMP reverses the effect of zileuton in sickle primary erythroid progenitors. Since 
the L-arginine/nitric oxide synthase product, nitric oxide, activates soluble guanylate cyclase 
which  results  in  the  accumulation  of  cGMP,  we 
Fig 5. Effects of 8PCPT-cGMP on ZL-treated  erythroid progenitors isolated 
from patients with homozygous sickle cell anemia.  The experimental conditions 
were same as in Fig 3. The effect of 8-(4-chlorophenylthio)guanosine 3’,5’-cyclic 
monophosphate (8-PCPT-cGMP,10µM) on BFU-E colony growth (A) and Hb F 
synthesis (B) in zileuton-treated (ZL, 50µM) sickle erythroid progenitors was 
assessed.  Data are expressed as the mean ± SEM. n=7 in control (CON) and ZL 
treatment groups; n=4 in the ZL+ 8PCPT-cGMP treatment group. Each experiment 
was done in triplicate. * p < 0.001 compared with the CON and ZL + 8PCPT-cGMP 
treatment groups .
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postulated that the cell permeable cGMP analogue, 8-PCPT-cGMP,
24 would mimic L-arginine 
inhibition of ZL induction of Hb F and decrease of BFU-E  colony  growth. Using the same 
protocol described with L-arginine, sickle erythroid progenitors were treated with ZL (50µM) in 
the absence or presence of 8-PCPT-cGMP (10µM) and compared with ZL-treatment and control 
(no treatment) groups. 8-PCPT-cGMP, similar to that observed with L-arginine, reverses ZL 
(50µM) suppression of BFU-E colony growth and stimulation of Hb F synthesis (Fig 5A-B).
Nitric oxide synthase inhibition abrogates the L–arginine inhibitory effect on zileuton.
Nitric oxide synthase produces nitric oxide by converting L-arginine and molecular oxygen into 
citrulline and nitric oxide.
22,23 The previous data suggested that L-arginine plays a negative 
regulatory role in ZL-mediated induction of Hb F. To test this, the nitric oxide synthase inhibitor,
L-NMMA (100µM), was used to determine if the inhibitory effect of L-arginine on ZL-induced 
Hb F synthesis was mediated by nitric oxide production. This dose of L-NMMA was chosen 
based on previous studies demonstrating nitric oxide synthase inhibition.
25 Studies (n=4, in 
triplicate) with L-NMMA alone were performed initially using sickle erythroid progenitors 
compared to controls (no L-NMMA).  L-NMMA did not affect BFU-E colony growth or Hb F 
synthesis relative to control. Subsequent studies were performed comparing ZL or HU alone to 
ZL + L-NMMA and HU + LNMMA. Interestingly, L-NMMA did not effect ZL-mediated
inhibition of BFU-E colony growth or induction of Hb F synthesis. In contrast to ZL, L-NMMA 
did partially reverse the HU effects on BFU-E colony growth and Hb F synthesis (Table 2).
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 13
0
5
10
15
H
b
 
F
 
(
%
)
CON ZL ZL+ARG ZL+ARG
+LNMMA
* *
B
Fig 6
0
50
100
150
A
CON ZL ZL+ARG ZL+ARG
+LNMMA
B
F
U
E
 
C
O
L
O
N
I
E
S
/
 
3
 
x
 
1
0
5
M
N
C
* *
Table II.  Effects of N
G-monomethyl-L-arginine on zileuton and hydroxyurea mediated BFU-E colony growth and fetal 
hemoglobin production in erythroid progenitors.
BFU-E                     
Hb 
F(%)
n    
 4   
 4            
CON  
 124.4 + 1.3   
    1.8 + 0.2         
ZL
 24.3 + 2.3
  11.5 + 0.6
 ZL+LNMMA
    27.5 + 2.3
      9.4 + 0.7
HU   
   8.2 + 0.9 
  19.7 + 0.6          
  HU+LNMMA
 *20.8 + 1.7
 *14.8 + 1.1
BFU-E = burst forming unit-erythroid, Hb F = fetal hemoglobin, CON = control
ZL = zileuton (50µM), LNMMA = N
G-monomethyl-L-arginine (100µM), HU = hydroxyurea (100µM)
* p< 0.01 compared to HU alone
Fig 6A and B demonstrate that L-NMMA reverses the L-
arginine effect on ZL in sickle erythroid progenitors 
resulting in restoration of decreased numbers of BFU-E 
colonies and stimulation of Hb F synthesis.
These data, cumulatively, support the hypothesis that nitric oxide plays an inhibitory role in 
Hb F induction by ZL and supports previously reported studies that nitric oxide at least in part 
facilitates the synthesis of Hb F synthesis by HU.
Fig 6. Effects of L-arginine and L-NMMA  on zileuton-treated erythroid 
progenitors isolated from patients with homozygous sickle cell anemia. The 
experimental conditions were the same as in Fig 3.   L-arginine (ARG; 100µM) 
effects on zileuton-treated erythroid progenitors in the absence and presence of the 
nitric oxide synthase inhibitor, LNMMA (100µM) were assessed. The number of 
BFU-E colonies (A) and percent Hb F (B) were measured as described in the 
Methods.  Data are expressed as mean ± SEM. n=7, control (CON); n=7, zileuton 
(ZL)-treated; n=5, ZL + L-arginine (ARG);  and n=4, ZL+ ARG+LNMMA-treated 
erythroid progenitors. Each experiment was done in triplicate. * p<0. 001 compared 
with CON and ZL+ARG.
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Discussion
ZL is a selective inhibitor of 5-LO and structural analog of HU 
1,2 that is currently being
used as an anti-inflammatory agent in the treatment of asthma.
26-31 To date there are no published 
studies that address the potential significance of ZL as a therapeutic agent in the treatment of 
sickle hemoglobinopathies. HU is the only drug currently approved for the treatment of SCD that 
is known to ameliorate its most common symptom, pain 
3 and common complications associated 
with death, including the acute chest syndrome.
32,33 The amelioration of symptoms by HU occurs 
at least in part through its ability to stimulate Hb F synthesis. Exactly how HU stimulates Hb F 
synthesis is not known.
In the present study, an erythroid cell culture system and K562 cells were utilized to 
study the effects of ZL on BFU-E colony growth, Hb F synthesis and ￿-globin mRNA synthesis. 
In addition, studies were performed which analyzed the role of the nitric oxide/cGMP pathway in
regulating  Hb  F  induction  in  primary  sickle  erythroid  progenitors.  In  this  study  the  major 
findings were: 1) ZL induced ￿-globin mRNA synthesis in K562 cells; 2) ZL induced Hb F 
synthesis  in  normal  and  sickle  primary  erythroid  progenitors;  3) the  nitric  oxide  donor,  L-
arginine, and cGMP analogue, 8-PCPT-cGMP, blocked ZL-induced Hb F synthesis; and 4) the 
nitric oxide synthase inhibitor, L-NMMA, blocks the L–arginine inhibitory effect on ZL. These 
observations  strongly  support  that  the  in  vitro  effects  of  ZL  are  at  least  in  part  negatively 
regulated through a nitric oxide-dependent pathway. Unlike ZL, L-arginine did not affect HU 
induction of Hb F. Furthermore, L-NMMA had no effect on ZL induction of Hb F. In contrast, 
L-NMMA partially abrogates the decrease in number of BFU-E colonies and increase in Hb F 
synthesis  seen  with  HU. These  observations  strongly  suggest  that  the  role  of  nitric  oxide
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signaling  in  regulating  ZL  and  HU  induction  of  Hb  F  synthesis  occur  through  different 
mechanisms.
Previously, we and others demonstrated the ability of  HU to induce ￿-globin mRNA 
production  at  the  transcriptional  level.
6,34
Thus  the  experimental  data  supports  a  multi-level 
mechanism for Hb F induction and the antisickling effects of HU therapy.  In this study, a dose 
response curve for ZL versus BFU-E colony number was established similar to that previously 
shown for HU.
6 These data suggest cytotoxicity plays a role in the mechanism of action for Hb F 
synthesis by ZL as well. Our data clearly demonstrated a comparable ability of ZL to induce ￿-
globin  gene  expression  at  the  transcriptional  level  and  suggest  ZL  may  have  clinical  utility 
similar to that reported with HU in the treatment of sickle hemoglobinopathies.  Furthermore, the 
concentrations of ZL used in this study are pharmacologically achievable with standard dosing 
previously reported in patients with asthma. 
35 
The  nitric  oxide-dependent  activation  of  soluble  guanylate  cyclase-protein  kinase  G 
pathway  in  primary  erythroblast  constitutes  a  mechanism  that  regulates  expression  of  the ￿-
globin gene 
12 by HU. In this study, the effect(s) of the nitric oxide donor, L-arginine,
22,23 on ZL 
induction of Hb F in primary sickle erythroid progenitors in culture was assessed. L-arginine 
dose-dependently blocked ZL-mediated induction of Hb F and caused the BFU-E colony number 
and Hb F percent to return to control values. This suggested that ZL-mediated increased Hb F 
synthesis through a cytotoxic pathway that is nitric oxide dependent. L-arginine and molecular 
oxygen in the presence of nitric oxide synthase produces citrulline and nitric oxide that activates 
soluble guanylate cyclase and increase intracellular cGMP accumulation.
22 Administration of the 
cell  permeant  cGMP  analogue,  8-PCPT-cGMP  mimicked  L-arginine  effects  suggesting  the 
upstream activation of nitric oxide is required to achieve ￿-globin inhibition. The role of L-
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arginine as a nitric oxide donor is supported by results obtained with the nitric oxide synthase 
inhibitor, L-NMMA. L-NMMA in the presence of ZL and L-arginine resulted in the restoration 
of Hb F induction and  a decrease in the number of  BFU-E colonies by  ZL. These findings 
cumulatively support that ZL increases Hb F synthesis and decreases the number of BFU-E 
colonies  through  a  pathway  that  is  at  least  in  part negatively  regulated  by  nitric  oxide. In 
addition, the ZL dose-response data suggest cytotoxicity plays a role in the mechanism of action 
for Hb F synthesis by ZL and HU. In contrast to ZL, L-arginine did not have any effect on sickle 
erythroid progenitors treated with HU. However, L-NMMA partially antagonized HU induction 
of Hb F and the decrease in BFU-E colony number. These data demonstrate that nitric oxide
plays a negative role in Hb F synthesis induced by ZL in contrast to a small but significant 
positive regulatory role in HU-mediated induction of Hb F synthesis.
Ikuta,  et  al,  recently  demonstrated  that  soluble guanylate  cyclase  activators  or 
analogs increased ￿-globin in K562 cells and human erythroid progenitors. In addition, hemin 
and butyrate-mediated ￿-globin induction was prevented by inhibiting soluble guanylate cyclase 
or  cGMP-dependent  protein  kinase.
12 Subsequently,  Cokic  et  al, demonstrated  that  S-
nitrosocysteine, a nitric oxide donor, induced ￿-globin mRNA and Hb F protein in K562 cells 
and human erythroid progenitors.
13 Both S-nitrosocysteine and HU increased cGMP levels and 
guanylate cyclase inhibitors abolished S-nitrosocysteine and HU-induced ￿-globin expression. In 
this study, L-arginine (100µM), a precursor to nitric oxide, did not stimulate Hb F synthesis over 
a 14 day period in cultured sickle erythroid progenitors. Whether or not L-arginine induces ￿-
globin  mRNA  in  sickle  erythroid  progenitors  was  not  assessed.  Although  L-arginine  is  a 
precursor  to  nitric  oxide,  studies  performed  utilizing  HU  and  L-arginine  did  not  mirror  the 
findings  of  a  nitric  oxide-dependent  pathway  reported  by  Cokic,  et  al,  with  the  nitric  oxide 
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donors, S-nitroscysteine and HU on Hb F synthesis. However, the nitric oxide synthase inhibitor, 
L-NMMA  did  partially  antagonize  the  HU  effects.  The  lack  of  an  L-arginine  effect  in  the 
presence of  L-NMMA suggest that the basal level of nitric oxide may be more significant in 
defining the physiologic significance of nitric oxide in HU induction of Hb F synthesis. While 
Cokic,  et  al,  suggest  that  nitric  oxide  releasing  or  potentiating  agents  may  have  potential 
therapeutic benefit, L-arginine is not supported by our study to be such an agent. Our data does 
not  rule  out  the  possibility  that  specific  nitric  oxide  donors  directly  stimulate  the  ￿-globin
promoter, however, it highlights the importance of evaluating potential ￿-globin inducers in the 
context of L-arginine, the major dietary source of nitric oxide.
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     Table I.  Effects of zileuton on BFU-E colony growth and fetal hemoglobin production in primary erythroid cultures.
Zileuton Concentrations (µM)
0 25 50 75 100
Patient 
No.
BFU-E 
 
Hb F BFU-E 
 
Hb F BFU-E 
 
Hb F BFU-E 
 
Hb F BFU-E 
 
Hb F
1     87    2     61      4     47     7       27          11     12     14
2   135    7     91     11     72    14       43    18       7    21
3
4                
  148
    93
 2
   3
  137
    86
     3
     5
    62
    66 
     6
     7
      23
      34
   11
     9
    13
    21
   13
   16
Mean     93    3 93.8   5.8  61.8    8.5    31.8  12.3   13..3 16.0
± SEM  15.2 1.2 15.8   1.8   5.3    1.8      4.4    2.0    2..9   1.8
￿ value __ __ > 0.05 >0.05 < 0.01 > 0.05 < 0.01 < 0.01 < 0.01        <0.01
 BFU-E= burst forming unit-erythroid, Hb F= fetal hemoglobin in percent (%)
￿ value represent a comparison of BFU-E colonies and Hb F in the absence of zileuton (0µM) versus 25 to 100µM 
   concentrations.
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Table II.  Effects of N
G-monomethyl-L-arginine on zileuton and hydroxyurea mediated BFU-E colony growth and fetal 
hemoglobin production in erythroid progenitors.
BFU-E                   
Hb 
F(%)
n    
 4   
 4            
CON  
 124.4 + 1.3   
    1.8 + 0.2         
ZL
 24.3 + 2.3
  11.5 + 0.6
 ZL+LNMMA
    27.5 + 2.3
      9.4 + 0.7
HU   
   8.2 + 0.9 
  19.7 + 0.6          
  HU+LNMMA
 *20.8 + 1.7
 *14.8 + 1.1
BFU-E = burst forming unit-erythroid, Hb F = fetal hemoglobin, CON = control
ZL = zileuton (50µM), LNMMA = N
G-monomethyl-L-arginine (100µM), HU = hydroxyurea (100µM)
* p< 0.01 compared to HU alone
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Figure Legends
Fig. 1. ￿-Globin gene induction by zileuton in K562 cells.  K562 cells were treated with 
zileuton (ZL) at 20 to 100µM  concentration or hydroxyurea (HU) 50 to 100µM  concentrations 
for comparison.  ￿ globin mRNA levels were quantitated by RNase protection assay (RPA) with 
a human ￿ (Hu￿) and internal control gylcearaldehyde-3-phosphate dehydrogenase (GAPD) 
probes to yield protected fragments of 170-bp and 316-bp respectively.  Panel A contains a 
representative RPA gel showing the mRNA bands for ZL treated cells on the left and HU treated 
cells on the right.  Panel B shows the quantitative values for Hu￿ and GAPD mRNA production 
by phosphorimager analysis.  The untreated K562 samples (0 µM) were normalized to one (black 
bars).  The total increase in ￿ mRNA was calculated as a ratio to GAPD to control for variations 
in sample loading for ZL (white bars) or HU (gray bars) treated K562 cells.  Sodium butyrate 
(NB, gray striped bars) and hemin (HE, white striped bars) were used as positive control for ￿
gene induction.  *2= NB at a 2 mM concentration.  
Fig. 2.   BFU-E colony growth and fetal hemoglobin production in the presence of zileuton 
for sickle cell and normal individuals in methylcellulose culture.  Peripheral blood 
mononuclear cells were cultured as described in Material and Methods.  The results are 
expressed as the number of BFU-E colonies per 3 X 10
5
mononuclear cells (MNC).  White bars 
represent sickle cell and gray bars normal samples.  Panel A demonstrates the BFU-E colonies 
on day 14 in the presence of zileuton at 0 to 100 µM concentrations.  Panel B represents Hb F for 
sickle cell (white bars) and normal samples (gray bars).  Note Hb F induction for both groups 
tested.
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Fig 3.  Effects of increasing concentrations of L-arginine on zileuton treated erythroid 
progenitors isolated from patients with homozygous sickle cell anemia.  Cells were cultured 
on methylcellulose culture media and treated with zileuton (100µM) as described in methods.  L-
arginine (10-100µM) was added at the beginning of the incubation period.  The number of BFU-
E colonies (￿-￿) and levels of hemoglobin F (Hb F, ￿-￿) were measured after 14 days of 
incubation.  Data are expressed as mean ± SEM of 4 experiments done in triplicate.  *p<0.001 
c/w baseline (BL); BL denotes the number of BFU-E colonies or percent Hb F measured in 
cultured cells not treated with zileuton. The 0µM point denotes the number of BFU-E colonies or 
percent Hb F measured in cultured cells treated with zileuton alone.  ￿ p< 0.01 c/w L-arginine, 
0µM ; ￿ p< 0.05 c/w L-arginine, 0µM. ￿ p<0.001 c/w L-arginine, 0µM.
Fig 4. Effects of L-arginine and L-NMMA on hydroxyurea-treated  erythroid progenitors 
isolated from patients with homozygous sickle cell anemia.  The experimental conditions 
were the same as in Fig 3.  L-arginine (ARG, 100µM) effects on hydroxyurea (HU)-treated 
(100µM) erythroid progenitors in the absence and presence of the nitric oxide synthase inhibitor, 
N
G-monomethyl-L-arginine (L-NMMA,100µM) were assessed. The number of BFU-E colonies 
(A) and percent Hb F (B) were measured as described in the Methods.  Data are expressed as 
mean ± SEM. n = 4 in each group. Each experiment was done in triplicate. * p < 0.001 compared 
with control (CON).
Fig 5. Effects of 8PCPT-cGMP on ZL-treated  erythroid progenitors isolated from patients 
with homozygous sickle cell anemia.  The experimental conditions were same as in Fig 3. The 
effect of 8-(4-chlorophenylthio)guanosine 3’,5’-cyclic monophosphate (8-PCPT-cGMP,10µM) 
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on BFU-E colony growth (A) and Hb F synthesis (B) in zileuton-treated (ZL, 50µM) sickle 
erythroid progenitors was assessed.  Data are expressed as the mean ± SEM. n=7 in control 
(CON) and ZL treatment groups; n=4 in the ZL+ 8PCPT-cGMP treatment group. Each 
experiment was done in triplicate. * p < 0.001 compared with the CON and ZL + 8PCPT-cGMP 
treatment groups.
Fig 6. Effects of L-arginine and L-NMMA  on zileuton-treated erythroid progenitors 
isolated from patients with homozygous sickle cell anemia. The experimental conditions were 
the same as in Fig 3.   L-arginine (ARG; 100µM) effects on zileuton-treated erythroid 
progenitors in the absence and presence of the nitric oxide synthase inhibitor, LNMMA (100µM) 
were assessed. The number of BFU-E colonies (A) and percent Hb F (B) were measured as 
described in the Methods.  Data are expressed as mean ± SEM. n=7, control (CON); n=7, 
zileuton(ZL)-treated; n=5, ZL + L-arginine (ARG);  and n=4, ZL+ ARG+LNMMA-treated 
erythroid progenitors. Each experiment was done in triplicate. * p<0. 001 compared with CON 
and ZL+ARG.
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Fig 5
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